Hikma Pharmaceuticals Share Discussion Threads

[montyhedge] 04/8/2022 08:45

I suppose chance will be out of the FTSE 100 next review on the market cap valuation.

[mjneish] 04/8/2022 08:27

I've just crunched a few numbers, using a conservative take on today's figures and guidance on full-year revenue and margin.

Core operating profit for the full year 2022 comes to just shy of $680 million compared to $632 million last year. This comes as a surprise, since one would have expected an overall decline.

I need to check the figures and will gladly share here if anyone is interested.

[montyhedge] 04/8/2022 08:19

Disappointing bears were right.

[scepticalinvestor] 04/8/2022 08:12

Thankfully dumped half my syock yesterday in anticipation. Will waot for a blunce to dump the rest. Siggi was the main driver in growth here

[blue59] 04/8/2022 08:11

Years of dividends wiped out in the first few minutes.

[suetballs] 04/8/2022 08:09

And here comes the expected fall in share price
I suppose the dividend is up.
Suet

[suetballs] 04/8/2022 07:43

Well there's the answer - weaker pricing in generics.
Although generics expected to return to growth in 2023.
Suet

[montyhedge] 03/8/2022 15:10

Wonder if bears closing just in case figures might be half decent,

[montyhedge] 03/8/2022 14:34

Been creeping up slowly, always two steps forward, one back.

[robertball] 01/8/2022 16:47

Think that's a bit simplistic. Value always comes out in the end and was expecting Hikma to be @£32 at this stage. Oh well

[montyhedge] 01/8/2022 13:53

True, not one SELL by an analyst.

[adamb1978] 01/8/2022 13:13

Broker target prices are useless in my view. Typically follow the news rather than lead the news

The company is trading on only a 11x PE and the only other time in the last 20 years that its dropped sub 10x aside from recently was late 2008.

Unless analyst forecasts are badly wrong and this starts to shrink, the price IMO is likely far too low. Even if earnings were flat, you'd make say 7%+ based on the share buy back (assume market cap remains flat but fewer shares) plus the divi.

As always, you can never be certain and making investments is simply a process of placing a series of reasoned bets where you feel there is more upside potential than downside. Personally I believe the risk is assymetric here

[scepticalinvestor] 01/8/2022 08:45

Make or break thurs i think. Under 10 GBP if numbers are off

[montyhedge] 01/8/2022 08:21

That maybe rectified on Thursday. At the moment seems a crazy low valuation, all will be revealed 4th August.

[mjneish] 30/7/2022 12:11

If we're going to keep regurgitating broker price forecasts, at least we could try to be objective about it.

Of 12 analysts, 10 quote "buy" and 2 quote "hold" at the moment.

The low, medium and high price targets are 1900p, 2367p and 2937p.

This is from IBKR.

It's rare to see a broker price target that is below the current price anyway.

[montyhedge] 29/7/2022 11:34

Interims next Thursday 4th Aug, another dividend rise the same as it has been for last 15 years. If decent perhaps get on its way to Barclays target 2500p.

[blue59] 28/7/2022 21:27

Don’t you ever get bored of being wrong?

[montyhedge] 28/7/2022 10:41

It will end the day up, forward momentum to strong for bears, they are trying to get shareprice down.

[scepticalinvestor] 28/7/2022 08:02

Always marked down...must still be a large holder dumping

[montyhedge] 27/7/2022 11:24

Quietly moving up to Barclays 2500p target.https://www.directorstalkinterviews.com/hikma-pharmaceuticals-plc-40.4-potential-upside-indicated-by-barclays/4121069274

[blue59] 27/7/2022 08:20

‘Tuck away’ = sitting on a fat loss and going nowhere any time soon!

[montyhedge] 23/7/2022 16:47

It's a tuck away, like the article says.https://www.fool.co.uk/2022/07/18/i-think-these-are-the-best-shares-to-buy-now-for-the-next-decade-2/